Total
0
Shares
Respiri (ASX:RSH) teams up with Pharmacy Guild to educate pharmacists on asthma management
  • eHealth software provider Respiri (RSH) has signed a service agreement with the Pharmacy Guild of Australia to help educate pharmacists on asthma management
  • The Pharmacy Guild represents over 5700 community pharmacies across the country
  • The asthma management will be an online training course with Guild Learning and Development
  • The program will also be supported by Respiri's wheezo's, which monitor asthma wheezing
  • On market close, Respiri is up 3.75 per cent and is selling shares for 8.3¢ each

eHealth software provider Respiri (RSH) has signed a service agreement with the Pharmacy Guild of Australia to help educate pharmacists on asthma management.

The Pharmacy Guild represents over 5700 community pharmacies across the country.

The agreement is for two years and the education program will be with Guild Learning and Development (GuildEd), which is a learning destination for Australian pharmacists, pharmacy assistants and interns.

The education program is an online training course for asthma patient management, in particular children. This will inform pharmacists to better help patients diagnosed with asthma.

The program will also be supported by Respiri's wheezo's, which monitor asthma wheezing.

Respiri CEO Marjan Mikel says with over 65,000 pharmacists practising in Australia, the company understands the importance of helping educate pharmacists.

"Respiri understands their [pharmacists] importance in helping patients with asthma better manage their condition ensuring a better health outcome and quality of life and the critical need for Respiri to build relationships with these key healthcare professionals to help them better understand how wheezo will help drive these patient outcomes," he said.

"By educating pharmacists, who are an important intermediary between an asthmatic patient and their doctor and who already sell a range of asthmatic devices within the pharmacy setting, we see them as a critical determinant in building sales momentum and significant growth within this important channel," he added.

On market close, Respiri is up 3.75 per cent and is selling shares for 8.3¢ each.


Subscribe


RSH by the numbers
More From The Market Herald
LBT Innovations (ASX:LBT) - CEO & Managing Director, Brent Barnes - The Market Herald

" LBT Innovations (ASX:LBT) partners with oneservice for APAS Independence

Biotech company LBT Innovations (LBT) has signed a partnership with oneservice for its APAS Independence product.
Avita Medical (ASX:AVH) - CEO, Dr Michael Perry - The Market Herald

" Avita Therapeutics (ASX:AVH) signs US$7.6M agreement with BARDA

Regenerative medicine company Avita Therapeutics (AVH) has teamed up with Biomedical Advanced Research and Development Authority (BARDA) for its RECELL System.
Race Oncology (ASX:RAC) - COO, Dr Daniel Tillett - The Market Herald

" Race Oncology (ASX:RAC) secures $3M from biotech investors

Race Oncology (RAC) has secured a $3 million strategic investment from three biotechnology investors.
Imagion Biosystems (ASX:IBX) - CEO & Executive Chairman, Bob Proulx - The Market Herald

" Imagion Biosystems (ASX:IBX) gains access to Boston University’s imaging tech

Cancer detection company Imagion Biosystems (IBX) will work with Boston University on the next generation of imaging technology.